Driven by the dual factors of an aging population and rising national health awareness, the number of surgeries in comprehensive hospitals in China has been continuously increasing. In 2019, the national surgical volume exceeded 59 million cases. Based on an average use of 15-20 dressings per surgery after the operation, this has created a market demand for around 1 billion medical dressings per year, equivalent to over 2.75 million clinical consumptions per day!

In addition, the demand for wound treatment management such as outpatient dressing changes and chronic wound care has been increasing year by year. In 2023, the market size of medical dressings in China is approximately 12.371 billion yuan, a year-on-year increase of 13.64%.

Qianshi® not only revolutionizes the wound care experience, bringing comfort and convenience to patients, but also reduces the frequency of dressing changes, significantly lowering the workload on medical staff and enhancing medical efficiency. Its unique technological advantages and outstanding clinical performance set it apart in the market, with substantial potential for market expansion and development. Taking Sichuan University West China Hospital as an example, this top-tier tertiary hospital completed as many as 187,200 surgeries in 2023. Following the conventional postoperative care process, each surgery typically requires a dressing change once a day, with the entire postoperative care process using 15 to 20 dressings. Based on these calculations, the annual usage of dressings at just this hospital alone could exceed 3.5 million pieces. However, if Qianshi® is used in postoperative care, its characteristics such as wound visibility, waterproof and antibacterial properties, reversible absorption and permeation, as well as its ability to promote healing and reduce scarring, mean that patients would only need 3 dressings throughout the entire postoperative care process. In this case, the annual usage of dressings at the hospital would be sharply reduced to 560,000 pieces. From a market perspective, its potential market capacity is estimated to exceed 100 million yuan.

Taking Zhejiang Provincial People's Hospital, a provincial tertiary hospital, as an example, the number of surgeries in 2023 is 93,400, and the potential market size for using Qianshi® post-surgery exceeds 50 million yuan per year. Similarly, taking Zhengzhou Central Hospital, a municipal tertiary hospital, as an example, with an annual surgery volume of 60,000, if Qianshi® is used post-surgery, the potential market size for a single hospital exceeds 30 million yuan per year. Therefore, for distributors, entering a single hospital can secure a procurement amount in the tens of millions, and this wave of wealth brought by medical upgrades is unstoppable.

QianShi® Visible Waterproof Dressing, the first domestically produced visible waterproof functional dressing in China, matches the performance of imported products and offers higher cost-effectiveness, currently receiving widespread clinical acclaim and successfully entering numerous large tertiary hospitals across the country. To better meet the diverse clinical needs, the research and development team at GuiLing Medical has optimized and upgraded the performance of the QianShi® Visible Waterproof Dressing (Class II), earning the only Class III registration certificate for a visible waterproof dressing in China (product name: QianShi® Pro). This breakthrough resolves the regional restriction issues for dressing promotion within the country.

(Class II registration certificate number: Zhe Medical Device Registration Approval 20222140054)

(Class III registration certificate number: National Medical Device Approval 20233141987)

Quansi® has favorable market access conditions in China, with basic coverage and charging realized across the country. Some leading regions such as Beijing, Shanghai, Jiangsu, and Hubei can be reimbursed by medical insurance, ensuring smooth and compliant hospital entry.

In the international market, QuanVision® has also received FDA certification in the United States, marking the recognition of its superior performance in terms of effectiveness and quality safety by international professional organizations, thus obtaining a passport to enter the U.S. market.

To further strengthen channel collaboration, GuiLing Medical sincerely invites channel partners from all over the world. GuiLing will provide comprehensive academic promotion support and share clinical case databases, among other resources, regardless of the market. Additionally, GuiLing will implement exclusive area protection policies to help dealers rapidly expand their terminal markets and achieve mutually beneficial development.

Genesis Medical is a leading medical device company in China, focusing on wound care and advancing into the field of diabetic foot from orthopedics, with an aim to provide comprehensive solutions in niche disease areas. Adhering to the principle of striving for "top three in the industry," the company has been driving innovation to layout three major product lines: precision surgery, advanced care, and healthy living. One of its star products, the MachDao® efficient debridement system for precise limb preservation, is among the few domestic innovations that have broken through key "chokepoint" technologies. This breakthrough has laid a solid foundation for breaking the monopoly of imports and reducing medical costs!

Currently, Gui Ling Medical has established a comprehensive wound repair solution centered around the MaHe Knife®, Quan Shi® system, and Quan Hu® negative pressure wound therapy system, aiming to achieve a splendid transformation from import substitution to surpassing imports through its outstanding product performance and pricing advantages.

In the future, GuiLing Medical will uphold the corporate vision of "leading medical technology and dedicated to benefiting the country and its people." Driven by innovation, it will increase efforts in developing new products, continuously optimize production processes, strengthen quality control, and strive to enhance international competitiveness, offering more high-quality medical options for patients and consumers both at home and abroad!